chemotherapy-induced peripheral neuropathy in patients with cancer. Idiopathic peripheral autonomic neuropathy
Conditions
Interventions
Intervention 1: Intervention group: Patients undergoing chemotherapy with symptoms of peripheral neuropathy first receive memantine at a dose of 5 mg for three days, and every three days 5 mg is added
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: People with any malignancy who have had grade 2 or higher neuropathy following chemotherapy
Exclusion criteria
Exclusion criteria: Patients with hypertension Acute heart failure type 1 & 2 diabetes mellitus peripheral vascular disease 285/5000Patients taking drugs (amantadine, ketamine, dextromethorphan, L-dopa; dopaminergic, anticholinergic agonists, barbiturates, neuroleptics, IMAO, antispasmodics, dantrolene or baclofen, phenytoinquinotine, cimetidine, ranitidine And warfarin) alcohl use People of reproductive ages, pregnancy and lactation People taking other neuropathic medications such as gabapentin, pregabalin and dologestin Patients with brain or leptomeningeal metastasis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of neuropathic symptoms. Timepoint: At PRE intervention (baseline phase) & 8 weeks after intervention. Method of measurement: McGill pain questionnaire, Neuropathic Pain, Neuropathic Pain Symptom Inventory. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contactsaba Ghaffary
Tabriz University of Medical Sciences
Outcome results
None listed